Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Aug 23

PMID 25148412

Citations 16

Authors

Daniel Schmidt

Christian Kollan

Gerd Fatkenheuer

Eugen Schulter

Hans-Jurgen Stellbrink

Christian Noah

Bjorn-Erik Ole Jensen

Matthias Stoll

Johannes R Bogner

Josef Eberle

Karolin Meixenberger

Claudia Kucherer

Osamah Hamouda

Barbara Bartmeyer

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed trends in the proportion of transmitted (TDR) and acquired (ADR) HIV drug resistance and associated mutations between 2001 and 2011 in the German ClinSurv-HIV Drug Resistance Study.

Method: The German ClinSurv-HIV Drug Resistance Study is a subset of the German ClinSurv-HIV Cohort. For the ClinSurv-HIV Drug Resistance Study all available sequences isolated from patients in five study centres of the long term observational ClinSurv-HIV Cohort were included. TDR was estimated using the first viral sequence of antiretroviral treatment (ART) naïve patients. One HIV sequence/patient/year of ART experienced patients was considered to estimate the proportion of ADR. Trends in the proportion of HIV drug resistance were calculated by logistic regression.

Results: 9,528 patients were included into the analysis. HIV-sequences of antiretroviral naïve and treatment experienced patients were available from 34% (3,267/9,528) of patients. The proportion of TDR over time was stable at 10.4% (95% CI 9.1-11.8; p for trend = 0.6; 2001-2011). The proportion of ADR among all treated patients was 16%, whereas it was high among those with available HIV genotypic resistance test (64%; 1,310/2,049 sequences; 95% CI 62-66) but declined significantly over time (OR 0.8; 95% CI 0.77-0.83; p for trend<0.001; 2001-2011). Viral load monitoring subsequent to resistance testing was performed in the majority of treated patients (96%) and most of them (67%) were treated successfully.

Conclusions: The proportion of TDR was stable in this study population. ADR declined significantly over time. This decline might have been influenced by broader resistance testing, resistance test guided therapy and the availability of more therapeutic options and not by a decline in the proportion of TDR within the study population.

Citing Articles

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir.

Sammet S, Touzeau-Romer V, Wolf E, Schenk-Westkamp P, Romano B, Gersbacher E Infection. 2023; 51(6):1823-1829.

PMID: 37526898 PMC: 10665222. DOI: 10.1007/s15010-023-02075-y.

Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.

Miranda M, Pingarilho M, Pimentel V, do Rosario O Martins M, Kaiser R, Seguin-Devaux C Front Microbiol. 2022; 13:846943.

PMID: 35495657 PMC: 9044068. DOI: 10.3389/fmicb.2022.846943.

Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations.

Pingarilho M, Pimentel V, Diogo I, Fernandes S, Miranda M, Pineda-Pena A Viruses. 2020; 12(11).

PMID: 33143301 PMC: 7693025. DOI: 10.3390/v12111238.

Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001-2018.

Stecher M, Chaillon A, Stephan C, Knops E, Kohmer N, Lehmann C Emerg Infect Dis. 2020; 26(10):2439-2443.

PMID: 32946725 PMC: 7510719. DOI: 10.3201/eid2610.191506.

Molecular Epidemiology of HIV-1 Infected Migrants Followed up in Portugal: Trends between 2001-2017.

Pimentel V, Pingarilho M, Alves D, Diogo I, Fernandes S, Miranda M Viruses. 2020; 12(3).

PMID: 32121161 PMC: 7150888. DOI: 10.3390/v12030268.

References

. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS. 2007; 21(8):1035-9. DOI: 10.1097/QAD.0b013e3280b07761. View

Marcelin A, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C . Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol. 2003; 72(1):162-5. DOI: 10.1002/jmv.10550. View

Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S . Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One. 2010; 5(10):e12718. PMC: 2951346. DOI: 10.1371/journal.pone.0012718. View

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh J . Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother. 2007; 60(4):843-8. DOI: 10.1093/jac/dkm274. View

Bennett D, Camacho R, Otelea D, Kuritzkes D, Fleury H, Kiuchi M . Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3):e4724. PMC: 2648874. DOI: 10.1371/journal.pone.0004724. View

de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C . An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005; 21(19):3797-800. DOI: 10.1093/bioinformatics/bti607. View

Lundgren J, Babiker A, El-Sadr W, Emery S, Grund B, Neaton J . Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008; 197(8):1145-55. DOI: 10.1086/529523. View

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I . Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207(8):1216-20. DOI: 10.1093/infdis/jit017. View

10.

Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh J, Knechten H . [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]. Dtsch Med Wochenschr. 2007; 132(18):977-82. DOI: 10.1055/s-2007-979365. View

11.

Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins J, de Wolf F . Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS. 2004; 18(11):1571-7. DOI: 10.1097/01.aids.0000131357.52457.33. View

12.

Brenner B, Roger M, Moisi D, Oliveira M, Hardy I, Turgel R . Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS. 2008; 22(18):2509-15. PMC: 2650396. DOI: 10.1097/QAD.0b013e3283121c90. View

13.

Kauf T, Davis K, Earnshaw S, Davis E . Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012; 6:155-64. PMC: 3295624. DOI: 10.2147/PPA.S28482. View

14.

Jones J, Taylor B, Wilkin T, Hammer S . Advances in antiretroviral therapy. Top HIV Med. 2007; 15(2):48-82. View

15.

de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I, Zahonero N . Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007; 23(7):879-85. DOI: 10.1089/aid.2005.0072. View

16.

Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin A, Brodard V . Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr. 2007; 46(1):12-8. DOI: 10.1097/QAI.0b013e318074eb73. View

17.

Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J . Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001; 344(7):472-80. DOI: 10.1056/NEJM200102153440702. View

18.

Tejerina F, Carlos Lopez Bernaldo de Quiros J . Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients. AIDS Rev. 2011; 13(4):227-33. View

19.

Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A . Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 2012; 345:e5253. PMC: 3424006. DOI: 10.1136/bmj.e5253. View

20.

Batzing-Feigenbaum J, Kollan C, Kuhne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, Hamouda O . Cohort profile: the German ClinSurv HIV project--a multicentre open clinical cohort study supplementing national HIV surveillance. HIV Med. 2010; 12(5):269-78. DOI: 10.1111/j.1468-1293.2010.00879.x. View